Taken together, these results indicate that while TP53/PIK3CA oncogenic mutations may play a role in tumorigenesis and to an extent tumor progression, ultimately other factors (e.g., immune profiles) may play a major role in regulating ICI responses. This evidence concerns the gene PIK3CA and neoplasm.